Friday, 24 January 2014

Emerging class of therapeutics represents a coming wave for developers and manufacturers

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.Ann M. Thayer, senior correspondent at C&EN, explains that ADCs are essentially molecular missiles. They are made up of a toxic payload (a drug) attached to an antibody that specifically seeks out sick cells, such as tumor cells. via Health News from Medical News Today Read More Here..


Lake forest health and fitness http://ift.tt/KPefDR

No comments:

Post a Comment